ESR1 and breast carcinoma: In January 2023, Elacestrant was approved by the FDA for the treatment of advanced breast cancer patients with ESR1 mutations developed after estrogen-deprivation therapy with aromatase inhibitors in combination with CDK4/6 inhibitor, also approved by EMA in July 2023 [57,59].